[1] Larjavaara S, Mäntylä R, Salminen T, et al. Incidence of gliomas by anatomic location. Neuro Oncol, 2007; 9, 319−25. doi:  10.1215/15228517-2007-016
[2] Xie J, Tang JX, Li Y, et al. ATM activation is key in vasculogenic mimicry formation by glioma stem-like cells. Biomed Environ Sci, 2024; 37, 834−49.
[3] Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005; 352, 987−96. doi:  10.1056/NEJMoa043330
[4] Ampie L, Woolf EC, Dardis C. Immunotherapeutic advancements for glioblastoma. Front Oncol, 2015; 5, 12. doi:  10.3389/fonc.2015.00012
[5] Dean M, Moitra K, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Hum Mutat, 2022; 43, 1162−82. doi:  10.1002/humu.24418
[6] Tabassum A, Samdani MN, Dhali TC, et al. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. J Mol Med (Berl), 2021; 99, 1293−309. doi:  10.1007/s00109-021-02088-w
[7] Tu ZW, Li KX, Ji QK, et al. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer, 2023; 23, 133. doi:  10.1186/s12885-022-10491-w
[8] Ling A, Löfgren-Burström A, Larsson P, et al. TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. Oncoimmunology, 2017; 6, e1356143. doi:  10.1080/2162402X.2017.1356143
[9] Cheng RY, Wang SQ. Cell-mediated nanoparticle delivery systems: towards precision nanomedicine. Drug Deliv Transl Res, 2024; 14, 3032−54. doi:  10.1007/s13346-024-01591-0